THERADIAG announced that it has obtained CE marking for four additional i-Tracker test kits for biotherapy monitoring. These four new i-Tracker kits have now obtained CE marking and their market launch has been registered with the French National Drug and Health Product Safety Agency. The Vedolizumab and Ustekinumab kits have been validated for drugs used to treat chronic inflammatory conditions in gastroentorology, such as Crohn’s disease and ulcerative colitis. These new i-Tracker test kits let clinicians fine-tune drug dosage in order to control the blood plasma and serum levels of biotherapies used to treat many chronic inflammatory conditions in gastroentorology. They are calibrated in accordance with the international standards issued by the World Health Organization (WHO). The CE marking of these new test kits extends the LISA Tracker range, continuing the strategy to develop thei-Track10 range in the leading hospitals and private labs in France and in all other countries where Theradiag operates.